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Introduction {#sec001}
============

Since being recognized as a distinct entity by the World Health Organization (WHO) in 2004 \[[@pone.0166897.ref001]\], Xp11.2 translocation renal cell carcinoma (Xp11.2 tRCC) has attracted broad attention \[[@pone.0166897.ref002]--[@pone.0166897.ref005]\]. The term of Xp11.2 tRCC derived from several different chromosomal translocations of Xp11.2 breakpoints and formatting of TFE3 fusion gene, which resulted in a significant overexpression of TFE3 protein in tumor cells. In recent years, renal cell carcinoma associated with t(6;11)(p21;q12)/TFEB gene fusions has been found to share similar pathology, epidemiology and genetics characteristics with Xp11.2 tRCC\[[@pone.0166897.ref006]\]. At the same time, both TFE3 and TFEB are members of microphthalmia-associated transcription (MiT) factor family. On the basis of these findings, WHO in 2016 newly designated Xp11.2 tRCC as MiT family translocation renal cell carcinoma \[[@pone.0166897.ref007]\].

Microscopically, Xp11.2 tRCC is similar to clear cell renal cell carcinoma (CCRCC) or papillary renal cell carcinoma (PRCC) \[[@pone.0166897.ref004], [@pone.0166897.ref008]\], which makes it difficult for pathologists to distinguish Xp11.2 tRCC from other tumor types by histological characteristics. Although immunohistochemical staining for TFE3 (TFE3-IHC) serves as the basic method for the diagnosis of Xp11.2 tRCC, numerous reports have shown that TFE3-IHC has fairly high false-positive rates and low predictive values, which results in misdiagnoses in patients \[[@pone.0166897.ref004], [@pone.0166897.ref009]--[@pone.0166897.ref011]\]. To date, TFE3 break-apart fluorescence in situ hybridization (FISH) is regarded as the best method to diagnose Xp11.2 tRCC due to its advantages of high sensitivity and specificity \[[@pone.0166897.ref002], [@pone.0166897.ref012]--[@pone.0166897.ref015]\]. In the current study, 34 cases of Xp11.2 tRCC were diagnosed using a TFE3 break-apart FISH probe. To assess whether ASPL-TFE3 RCC, one of the subtypes of Xp11.2 tRCC with a fusion pattern of t(x;17)(p11.2;q25), showed more aggressive progress than other subtypes, we used an ASPL-TFE3 dual-fusion FISH probe for the diagnosis of ASPL-TFE3 RCC. Both the TFE3 break-apart FISH probe and ASPL-TFE3 dual-fusion FISH probe were demonstrated to identify the TFE3 and ASPL-TFE3 fusion genes, respectively, in our previous investigations \[[@pone.0166897.ref011], [@pone.0166897.ref015]\].

Despite its low incidence, Xp11.2 RCC is more harmful than conventional RCC because the majority of patients present at advanced stages and invasive clinical courses \[[@pone.0166897.ref002]--[@pone.0166897.ref005], [@pone.0166897.ref016]\]. Surgical treatment, especially radical nephrectomy (RN), remains the most common strategy to treat Xp11.2 tRCC. The implementation of nephron-sparing surgery (NSS) in Xp11.2 RCC is rarely reported, although it has been confirmed safe and effective in conventional RCC by several large retrospective studies \[[@pone.0166897.ref017], [@pone.0166897.ref018]\]. Herein, the outcomes of patients receiving RN or NSS were compared to ascertain the effectiveness of NSS for these potentially aggressive tumors.

Patients and Methods {#sec002}
====================

Patients and diagnosed methods {#sec003}
------------------------------

The RCC patients were reviewed at Nanjing Drum Tower Hospital from January 2007 to February 2016, and the study was conducted from February to June 2016. All procedures were approved by the Medical Ethics Committee for human Experiments of Nanjing Drum Tower Hospital. This study involved the preoperative computed tomography (CT) characteristics, medical records, follow-ups and outcomes of patients. IHC staining was performed on formalin-fixed paraffin-embedded tissue sections with a TFE3 antibody, and 2 (+) to 3 (+) nuclear TFE3 immunoreactivity in more than 10% of cells was considered positive. Polyclonal break-apart probes for TFE3 gene rearrangement at the Xp11.2 region were utilized on samples from patients who had a positive TFE3-IHC result on formalin-fixed paraffin-embedded tissue microarray slides. Of the 1,239 RCC patients, 82 cases showed positive reaction to TFE3-IHC, and 34 cases were eventually diagnosed as Xp11.2 tRCC by FISH. With the exception of one young female patient who lost to follow-up at the 88^th^ postoperative month, the other 33 cases were followed over a period ranging from 3 to 104 months. The clinicopathological characteristics and follow-up information of these patients are shown in [Table 1](#pone.0166897.t001){ref-type="table"}. To ascertain specific types of genetic changes in tumor cells, 23 cases (case 1 to case 23 in [Table 1](#pone.0166897.t001){ref-type="table"}) were subjected to the ASPL-TFE3 dual-fusion FISH assay, but case 24 to case 34 were not achieved due to the absent of tissue sections. All the patients have signed in informed written consents to have their medical record data used in research.

10.1371/journal.pone.0166897.t001

###### Clinical data of 34 cases of Xp 11.2 tRCC.

![](pone.0166897.t001){#pone.0166897.t001g}

  Case   Age (years)/Sex/Laterality   Symptom                           Tumor size (cm)   Operation   Final diagnosis   ACJJ stage      Adjuvant therapy   Follow-up (months) and outcome
  ------ ---------------------------- --------------------------------- ----------------- ----------- ----------------- --------------- ------------------ ----------------------------------------------
  1      21/F/R                       Symptomless                       4                 LRN         ASPL-TFE3 RCC     pT1aN0M0, I     None               60, Normal
  2      25/M/R                       Gross hematuria, Flank pain       7.1               LRN         ASPL-TFE3 RCC     pT2aN0M0, II    IT                 18, Normal
  3      35/M/R                       Symptomless                       6                 LRN         Xp11.2 RCC        pT1bN0M0, I     TMT                50, Lung metastasis in 11 months, stable now
  4      26/M/L                       Symptomless                       3.7               ORN         Xp11.2 RCC        pT1aN0M0, I     TMT                74, Normal
  5      39/F/R                       Symptomless                       13                ORN+VCTER   Xp11.2 RCC        pT3bN1M0, III   TMT                25, Died of liver and brain metastasis
  6      46/F/R                       Flank pain, Abdominal mass        5.8               ORN+VCTER   Xp11.2 RCC        pT3cN0M0, III   TMT                15, Died of lung metastasis
  7      22/F/R                       Gross hematuria                   3.9               LRN         ASPL-TFE3 RCC     pT1aN1M0, III   TMT                62, Died of bone metastasis
  8      26/F/R                       Gross hematuria                   5                 LRN         Xp11.2 RCC        pT1bN0M0, I     None               96, Normal
  9      7/M/L                        Gross hematuria                   3                 ORN         ASPL-TFE3 RCC     pT1aN0M0, I     None               104, Normal
  10     36/F/R                       Gross hematuria                   8.6               ORN+VCTER   ASPL-TFE3 RCC     pT3cN1M0, III   TMT                33, Died of liver metastasis
  11     30/F/R                       Symptomless                       3.2               RA+LNSS     Xp11.2 RCC        pT1aNxM0, I     TMT                63, Normal
  12     7/M/L                        Gross hematuria, Abdominal mass   10                ORN         Xp11.2 RCC        pT4N1M0, IV     None               65, Normal
  13     25/F/L                       Symptomless                       3.8               LRN         Xp11.2 RCC        pT1aN0M0, I     IT                 58, Normal
  14     24/F/R                       Symptomless                       3.9               LRN         Xp11.2 RCC        pT1aN0M0, I     IT                 42, Normal
  15     51/F/R                       Symptomless                       5                 LNSS        Xp11.2 RCC        pT1bNxM0, I     IT                 53, Normal
  16     27/F/R                       Gross hematuria, Flank pain       6                 LRN         Xp11.2 RCC        pT1bN0M0, I     IT                 53, Normal
  17     26/M/L                       Symptomless                       3.7               LNSS        Xp11.2 RCC        pT1aN0M0, I     IT                 18, Normal
  18     3/F/R                        Gross hematuria                   4                 ORN         Xp11.2 RCC        pT1aN1M0, III   None               71, Normal
  19     11/F/R                       Gross hematuria, Abdominal mass   5.6               ORN         Xp11.2 RCC        pT1bN0M0, I     None               88, Lost
  20     40/M/L                       Symptomless                       3.9               LRN         Xp11.2 RCC        pT1aN0M0, I     None               37, Normal
  21     19/F/L                       Symptomless                       5                 LRN         Xp11.2 RCC        pT1bN0M0, I     None               24, Normal
  22     38/M/R                       Gross hematuria, Flank pain       3                 LRN         ASPL-TFE3 RCC     pT1aN0M0, I     IT                 28, Normal
  23     29/M/L                       Symptomless                       3.5               LNSS        Xp11.2 RCC        pT1aN0M0, I     IT                 10, Normal
  24     25/F/R                       Gross hematuria                   8.1               LRN         Xp11.2 RCC        pT2aN0M0, II    None               91, Normal
  25     27/M/L                       Symptomless                       8.5               LRN         Xp11.2 RCC        pT3aN0M0, III   TMT                24, Recurred in 16 months
  26     22/F/R                       Gross hematuria                   5                 LRN         Xp11.2 RCC        pT1bN0M0, I     IT                 38, Normal
  27     45/M/R                       Symptomless                       5.5               LNSS        Xp11.2 RCC        pT1bNxM0, I     IT                 14, Normal
  28     25/F/R                       Gross hematuria                   3.5               LRN         Xp11.2 RCC        pT1aNxM0, I     IT                 13, Normal
  29     39/F/R                       Flank pain                        4.5               LNSS        Xp11.2 RCC        pT1bNxM0, I     IT                 11, Normal
  30     45/F/L                       Symptomless                       12                ORN         Xp11.2 RCC        pT3aN0M0, III   TMT                30, Recurred in 12 months
  31     30/F/L                       Symptomless                       9.5               LRN         Xp11.2 RCC        pT3aN0M0, III   TMT                20, Recurred in 14 months
  32     64/M/L                       Symptomless                       3                 LNSS        Xp11.2 RCC        pT1aN0M0, I     IT                 3, Normal
  33     55/F/R                       Symptomless                       3                 LNSS        Xp11.2 RCC        pT1aN0M0, I     IT                 8, Normal
  34     42/M/L                       Symptomless                       3.5               LNSS        Xp11.2 RCC        pT1aN0M0, I     IT                 4, Normal

ACJJ: American Joint Committee on Cancer; F: Female; IT: Immune therapy; L: Left; LNSS: laparoscopic nephron-sparing surgery; LRN: Laparoscopic radical nephrectomy; M: Male; ORN: Open radical nephrectomy; R: Right; RA: Radiofrequency Ablation; TMT: Targeted molecular therapy; VCTER: Vena cava tumor embolus resection.

Evaluation of clinical data {#sec004}
---------------------------

The clinical data consisted of epidemiological features (gender and age), clinical manifestations, general history, preoperative CT imaging (laterality, tumor size and boundary), treatment methods (surgery, immune therapy or targeted therapy), pathological features (TNM stages, TFE3-IHC staining and FISH results) and clinical outcomes (normal, recurrent or dead). All of these data for the 34 patients were retrospectively analyzed. TNM staging was reclassified in accordance with the 7^th^ American Joint Committee on Cancer (AJCC) staging criteria (2010). All of the patients were followed every 3 months during the first year, every 6 months during the following 4 years, and annually after 5 years until the time of death or loss to follow-up.

Statistical analyses {#sec005}
--------------------

Progression-free survival (PFS) was defined from the initiation of surgery to the date of disease progression or censoring at the time of last follow-up. Overall survival (OS) was defined as the time interval between the date of surgery and the date of death or last follow-up. PFS and OS curves were obtained by Kaplan--Meier analysis, and statistical comparisons were performed using the log-rank test. Multivariate Cox regression model was used to evaluate the predictive role of the factors that showed significance in the long-rank test. Univariate and multivariate analyses were performed using SPSS software version 16.0 (SPSS Inc., Chicago, IL, USA). GraphPad Prism software version 5.0 was used to generate the survival curves. P-values \<0.05 were considered statistically significant.

Results {#sec006}
=======

In total, 34 cases were identified encompassing 13 males and 21 females with a median age of 27 years (range of 3--64 years). Females with Xp11.2 tRCC in the age range of 18--45 years accounted for 81% of the patient population (17/21). With the exception of one patient who had a history of microcarcinoma thyroid in the previous 2 years, none of the patients had a history of tumors or chemotherapy. Nine of 34 (26%) patients underwent laparoscopic nephron-sparing surgery (LNSS) for the primary tumor, and the remaining 25 (74%) patients underwent open radical nephrectomy (ORN) or laparoscopic radical nephrectomy (LRN). Three of these latter patients who had inferior vena cava tumor thrombosis (cases 5, 6 and 10) underwent vena caval tumor thrombectomy simultaneously. The preoperative CT images for patients who underwent LNSS showed an isolated mass with a small diameter (\<7 cm) and well-defined boundary.

Postoperative AJCC staging showed that 25 cases were classified as stage I/II, while 9 cases were classified as stage III/IV. Thirty-four patients were followed with a mean time of 41 months (range was 3--104 months). Twenty-four of the stage I/II cases received satisfactory results during a mean follow-up time of 42 months, except for one stage I male who was diagnosed with lung metastasis at the 11^th^ postoperative month. However, for the stage III/IV patients, 7 adults who received surgery and postoperative adjuvant molecular-targeted therapy (receptor tyrosine kinase inhibitor sunitinib or sorafinib) developed distant metastases or local recurrence, while two children who underwent surgery alone did not show disease progression during 65 and 71 months of follow-up. Of the three recurrent patients, case 25 was found abdominal wall recurrence, and case 30 along with case 31 were found ipsilateral abdominal cavity recurrence. Secondary surgeries were preformed to resect the recurrent lesions. Unfortunately, there was still one patient (case 25) who experienced an additional recurrence. Importantly, 9 patients who underwent LNSS showed no evidence of progress with a mean follow-up of 20 months.

Of the 34 cases diagnosed as Xp11.2 tRCC by the use of FISH, 7 cases (21%) were originally misdiagnosed as CCRCC (2 cases), PRCC (4 cases), and unclassified renal cell carcinoma (1 case).

[Table 2](#pone.0166897.t002){ref-type="table"} summarizes each tested variable and the significance of variation. Univariate analysis showed that adjuvant treatment, TNM stage, regional lymph node metastasis and vena cava tumor thrombosis were risk factors for OS. In addition, maximum diameter, adjuvant treatment, TNM stage and vena cava tumor thrombosis were identified as risk factors for PFS (all P\<0.05). The Kaplan-Meier survival curves for OS and PFS according to TNM stage are shown in [Fig 1](#pone.0166897.g001){ref-type="fig"}. The OS and PFS curves according to vena cava tumor thrombosis are shown in [Fig 2](#pone.0166897.g002){ref-type="fig"}. The four pairs of PFS and OS curves depending on TNM stage and vena cava tumor thrombosis were distinctly tiered and statistically significant.

![**Survival curves of overall survival (A) and progression-free survival (B) between stage I/II and stage III/IV patients.** The overall survival and progression-free survival between stage I/II and stage III/IV in Xp11.2 tRCC were statistically significant.](pone.0166897.g001){#pone.0166897.g001}

![**Survival curves of overall survival (C) and progression-free survival (D) between inferior vena cava tumor thrombosis-positive and -negative patients.** The overall survival and progression-free survival between inferior vena cava tumor thrombosis-positive and -negative patients were statistically significant.](pone.0166897.g002){#pone.0166897.g002}

10.1371/journal.pone.0166897.t002

###### Kaplan-Meier univariate analysis of prognostic factors for overall survival (OS) and progression-free survival (PFS).

![](pone.0166897.t002){#pone.0166897.t002g}

  Variable                             Number (%)                   One-year overall survival rate   Three-year overall survival rate   Five-year overall survival rate   P value (Long-rank test)                 
  ------------------------------------ ---------------------------- -------------------------------- ---------------------------------- --------------------------------- -------------------------- ------------- -------------
  Age                                                                                                                                                                                                0.230         0.192
                                       \<18 years                   4(11.8%)                         100%                               100%                              100%                                     
                                       ≥18 years                    30(88.2%)                        96%                                84%                               60%                                      
  Sex                                                                                                                                                                                                0.182         0.554
                                       Male                         13(38.2%)                        100%                               100%                              100%                                     
                                       Female                       21(61.8%)                        94%                                86%                               81%                                      
  Symptom                                                                                                                                                                                            0.753         0.211
                                       Gross hematuria              13(38.2%)                        100%                               90%                               68%                                      
                                       Non-gross hematuria          21(61.8%)                        93%                                84%                               84%                                      
  Laterality                                                                                                                                                                                         0.172         0.967
                                       Left                         13(38.2%)                        94%                                81%                               61%                                      
                                       Right                        21(61.8%)                        100%                               100%                              100%                                     
  Operation                                                                                                                                                                                          0.488         0.179
                                       Radical nephrectomy          25(73.5%)                        96%                                86%                               69%                                      
                                       Partial nephrectomy          9(26.5%)                         100%                               100%                              100%                                     
  Maximum diameter                                                                                                                                                                                   0.199         **0.007**
                                       ≤7 cm                        26(76.5%)                        95%                                95%                               74%                                      
                                       \>7 cm                       8(23.5%)                         100%                               60%                               60%                                      
  Adjuvant treatment                                                                                                                                                                                 **0.016**     **\<0.001**
                                       Without                      9(26.5%)                         100%                               100%                              /                                        
                                       Immune therapy               15(44.1%)                        100%                               100%                              /                                        
                                       Targeted molecular therapy   10(29.4%)                        89%                                64%                               32%                                      
  TNM stage                                                                                                                                                                                          **0.002**     **\<0.001**
                                       Staged I / II                25(73.5%)                        100%                               100%                              100%                                     
                                       Staged III / IV              9(26.5%)                         88%                                59%                               29%                                      
  Lymph node metastasis                                                                                                                                                                              **0.018**     0.080
                                       Positive                     5(14.7%)                         100%                               60%                               30%                                      
                                       Negative                     29(85.3%)                        95%                                95%                               95%                                      
  Inferior vena cava tumorthrombosis                                                                                                                                                                 **\<0.001**   **\<0.001**
                                       Positive                     3(8.8%)                          67%                                /                                 /                                        
                                       Negative                     31(91.2%)                        100%                               100%                              82%                                      
  Fusion type                                                                                                                                                                                        0.280         0.439
                                       ASPL                         6(26.1%)                         100%                               78%                               39%                                      
                                       Non-ASPL                     17(73.9%)                        94%                                87%                               87%                                      
  Boundary                                                                                                                                                                                           0.088         **0.048**
                                       Clear                        15(44.1%)                        100%                               100%                              100%                                     
                                       Not clear                    19(55.9%)                        94%                                80%                               48%                                      

Multivariate analysis was performed using a Cox proportional hazards model to assess the independent prognostic value of clinicopathological features for PFS and OS. Considering that adjuvant treatment was closely associated with postoperative TNM stage, we excluded it when performing multivariate analysis to obtain a more reliable result. The Cox regression analysis result for PFS is shown in [Table 3](#pone.0166897.t003){ref-type="table"}. TNM stage (P = 0.015) and vena cava tumor thrombosis (P = 0.024) showed independent prognostic significance. However, Cox regression indicated no significant independent prognostic factor when analyzing OS.

10.1371/journal.pone.0166897.t003

###### Multivariate Cox regression analyses of progression-free survival.
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  Variable                              B        SE        Wald value   P value     HR (95%CI)
  ------------------------------------- -------- --------- ------------ ----------- ----------------
  Maximum diameter                      -0.056   0.159     0.124        0.725       0.693--1.291
  TNM stage                             3.102    1.270     5.962        **0.015**   1.844--268.066
  Lymph node metastasis                 -1.492   1.003     2.212        0.137       0.031--1.607
  Inferior vena cava tumor thrombosis   2.792    1.233     5.129        **0.024**   1.456--182.861
  Boundary                              11.613   234.618   0.002        0.961       0.000--5.635

Discussion {#sec007}
==========

Xp11.2 tRCC typically affects children and young adults under 45 years of age \[[@pone.0166897.ref003], [@pone.0166897.ref004], [@pone.0166897.ref019], [@pone.0166897.ref020]\] with a one-third incidence in juveniles and 0.2--5.0% incidence in adults \[[@pone.0166897.ref016], [@pone.0166897.ref021]--[@pone.0166897.ref023]\]. Unlike pediatric RCCs, cytogenetics is not routinely performed for adult RCCs due to the relatively lower incidence rate, which results in most misdiagnoses as conventional RCCs. Therefore, the exact frequency in adults is underestimated \[[@pone.0166897.ref021], [@pone.0166897.ref022]\], as inferred from our investigation. Compared with standard cytogenetics, TFE3-IHC has advantages of rapid diagnosis, high economy and high sensitivity in diagnosing Xp11.2 RCC. Thus, TFE3-IHC can be performed proactively as a screening test, and FISH can be performed as a verification test. Hirobe and Masumori suggested that the combination of TFE3-IHC and FISH is an effective method to diagnose Xp11.2 tRCCs, which can improve specificity and potentially eliminate false-positives resulting from overstaining \[[@pone.0166897.ref004]\].

In the current study, a predominance of young females and right side prevalence was observed, which is consistent with previous reports \[[@pone.0166897.ref004], [@pone.0166897.ref022], [@pone.0166897.ref024]\]. In the report by Argani on 28 cases of Xp11.2 tRCC, there was a strong female (22 cases, 79%) and a slight right (14/22, 64%) preference, of which 22 cases (79%) were younger than 45 years \[[@pone.0166897.ref022]\]. Choueiri et al. identified 15 Xp11.2 tRCCs, and female patients accounted for 80% \[[@pone.0166897.ref024]\]. Qu diagnosed 30 cases of Xp11.2 tRCC and reported that 18 cases (60%) were females, with 1/3 aged between 18 and 45 years and 17 of 30 cases showing a right side prevalence \[[@pone.0166897.ref002]\]. One probable explanation for the female predominance might be that females possess two X chromosomes while males only possess one, which leads to a higher incidence of X chromosome translocation. It remains unknown why the right side showed predominance. Due to an insufficient sample size, the actual frequency and mechanisms require further investigation.

With its aggressive biological behavior and local invasion tendency in adult, Xp11.2 tRCC trends to present with lymphatic and distant organ metastasis at diagnosis. To date, there is not yet a consensus regarding therapy, RN is recommended if possible \[[@pone.0166897.ref008]\]. Nevertheless, with the popularly utilized of NSS in recent year, part of the early stage Xp11.2 tRCC patients received NSS. Urologists and patients usually puzzled with the management between a completion nephrectomy and close surveillance when a patient was incidentally diagnosed with Xp11.2 tRCC after a partial nephrectomy. However, results from published studies reveal that the practice of NSS also produces favorable treatment outcomes in short-term follow-up studies \[[@pone.0166897.ref003], [@pone.0166897.ref018], [@pone.0166897.ref025]\]. Gorin and Ball reported that 4 patients who were treated with NSS remained alive without evidence of disease during a mean follow-up of 37 months \[[@pone.0166897.ref018]\]. Lim and You retrospectively analyzed 8 cases of Xp11.2 tRCC, and all of these patients underwent open or robotic NSS and were disease-free with a follow-up time of 18 to 47.6 months \[[@pone.0166897.ref003]\]. Herein, the treatment of Xp11.2 RCC by LNSS obtained a satisfactory result with a mean follow-up of 20 months. Even though, long-time follow-up is need as its well documented ability of recurrent late, especially PRCC-TFE3 RCC \[[@pone.0166897.ref005], [@pone.0166897.ref026]\].

Because pathological types are usually uncertain before surgery, radiologic and ultrasonic information may be the only reference to determine whether RN or NSS should be performed if a patient has a renal tumor. According to the literature, isolated masses with small diameters (\<7 cm) and well-defined boundaries are regarded as appropriate candidates for NSS \[[@pone.0166897.ref017], [@pone.0166897.ref020], [@pone.0166897.ref027], [@pone.0166897.ref028]\], which is based on the finding that tumors with small diameters and clear rims predicate positive prognosis. From our statistical outcomes, both small diameters (\<7 cm) and clear boundaries were protective factors for prognosis. Furthermore, Xiangming and colleagues reported that there was an inverse correlation between diameters and boundary, with larger diameters showing more indefinite boundaries \[[@pone.0166897.ref025]\]. As NSS offers oncological outcomes and preserves renal function comparable with that of RN, NSS should be considered if a young patient presents with a small lesion (\<7 cm) and distinct boundary, especially patients with anatomical or a functional solitary kidney.

Since chemotherapy and radiotherapy proved to be invalid for Xp11 tRCC, the optimal and reliable adjuvant treatment remains to be developed. According to several previous studies, interferon (IFN-a) and interleukin-2 (IL-2) do not produce a significant response in this type of tumor \[[@pone.0166897.ref021], [@pone.0166897.ref029]\]. Recently, the molecular-targeted therapy using a receptor tyrosine kinase inhibitor, e.g., sunitinib or sorafinib, was shown to be a treatment choice for patients with lymph node or distant metastases \[[@pone.0166897.ref024], [@pone.0166897.ref030]\]. Choueiri et al. retrospectively reviewed 15 adult patients with metastatic Xp11.2 tRCC, and they reported that 3 patients achieved a partial response, 7 patients had stable disease, and 5 patients developed progressive disease \[[@pone.0166897.ref024]\]. However, the patients in Choueiri's study were diagnosed by TFE3-IHC. In the study of Malouf, the researchers examined 21 cases of metastatic Xp11.2 tRCCs who received targeted therapy, and they reported that 7 patients achieved an objective response to sunitinib with a median PFS of 8.2 months compared to cytokine therapy with a median PFS of 2 months. In the current study, a 35-year-old male presented with lung metastasis at 11 months after surgery, and this patient then received targeted therapy for 8 weeks and survived during the postoperative follow-up of 50 months. However, all stage III adults who received ORN/LRN and targeted molecular therapy ultimately developed terminal or recurrent cancer. Giving the toxicity to growth, the usage of targeted therapy on juvenilities is usually limited, although trials have been reported \[[@pone.0166897.ref030], [@pone.0166897.ref031]\].

The literature shows that adults with Xp11 tRCC possess a grimmer prognosis than children, which is congruent with the data from our study, despite our finding from the univariate analysis indicated that age was not associated with prognosis due to the small sample size. For pediatrics, regional lymph node metastases do not necessarily predict poor prognosis \[[@pone.0166897.ref020], [@pone.0166897.ref023], [@pone.0166897.ref028], [@pone.0166897.ref032]\]. Geller et al. retrospectively reviewed 58 patients and found that children with lymph node-positive RCC in the absence of distant metastatic disease had a relatively favorable long-term prognosis with a survival rate (72.4%) nearly triple that of the adult controls \[[@pone.0166897.ref033]\]. Song et al. studied 22 cases of pediatric Xp11.2 tRCCs, including 12 stage III/IV patients, and reported that 13 patients were still alive and 2 had a terminal course with a postoperative follow-up of 6 months to 35 years \[[@pone.0166897.ref020]\]. Nevertheless, a meta-analysis showed that Xp11.2 tRCCs showed a poorer prognostic than non-Xp11.2 translocation carcinomas in children and young adults \[[@pone.0166897.ref034]\].

Similar to conventional RCCs, advanced TNM stage and inferior vena cava tumor thrombosis are the most significant factors that predict poor prognosis in Xp11 tRCC, which was verified by univariate and multivariate analyses in our study. Recently, Qu et al. \[[@pone.0166897.ref004]\] reported 30 cases of Xp11.2 tRCC diagnosed by FISH and showed that 11 of 14 stage III/IV patients presented with metastases of lung, liver or other organs, which was in contrast to the remaining 16 stage I/II patients. In the reports of Nesbitt et al., 20 of 37 patients with RCC with inferior vena cava tumor thrombus were alive after surgical resection, and the overall 2- and 5-year survival rates were 61.7% and 33.6%, respectively \[[@pone.0166897.ref035]\]. Nevertheless, the three patients with inferior vena cava tumor thrombosis in our investigation showed distant metastases and rapid termination of their life with a mean follow-up of 33 months, regardless of having undergone vena caval tumor thrombectomy and targeted molecular therapy.

In our investigation, 2 out of 6 ASPL-TFE3 RCC patients died due to multiple metastases. In the study by Ellis et al. \[[@pone.0166897.ref005]\], all of the published ASPL-TFE3 and PRCC-TFE3 cases were reviewed, and they reported that 24 out of 32 ASPL-TFE3 cases showed regional lymph node involvement, which was a higher incidence rate than that of PRCC-TFE3 cases. In the study by Komai et al. \[[@pone.0166897.ref036]\], 2 cases with ASPL-TFE3 RCC displayed metastasis, and one patient died of the disease. However, comparison of the survival time of Xp11.2 tRCC between ASPL fusion and non-ASPL fusion cases showed no difference by long-rank test in our study.

As its low-frequency, the reported Xp11.2 tRCCs which were diagnosed by FISH or PCR less than 150 all over the world. To date, this is one of the largest single-center clinical report on Xp11.2 tRCC confirmed by FISH. The data we published will undoubtedly enrich the literature base. There are some limitations to the current study. First, the sample size was insufficient due to the low incidence of this rare disease. Although the TFE3-IHC assay is sensitive to detect TFE3 in the screening of Xp11.2 tRCC, potential missed diagnoses may still exist. Second, the follow-up time was relatively short, especially for patients treated with NSS. Long-term follow-up is needed to assess the therapeutic effects of NSS. Third, only 6 cases were identified as genetic fusion types by the ASPL-TFE3 dual-fusion FISH assay, which did not allow the comparison between different subtypes of Xp11.2 tRCC to be performed. We are currently utilizing additional types of fusion probes to identify the genetic fusion types of those cases.

Conclusions {#sec008}
===========

Xp11.2 tRCC is a rare subset of RCC that mainly occurs in children and young females with gross hematuria. The combination of the TFE3-IHC assay and FISH analysis is an accurate and effective approach to screen and confirm, respectively, the diagnosis of Xp11.2 tRCC. Radical and partial nephrectomy constitute alternative treatments for patients with well-defined lesions measuring \<7 cm. The prognosis of adults is significantly inferior to that of children, especially for patients at advanced TNM stages and with inferior vena cava tumor thrombosis.
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###### The STROBE checklist of the current study.

This checklist contains items that reflected in our study according to STROBE guidelines.

(DOCX)

###### 

Click here for additional data file.
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